Mild cognitive impairment(MCI) is considered to be a potential transitional stage between normal cognitive function and dementia.

To determine comparatively the outcome of patients treated with different therapies.

There were included 193 subjects with MCI, aged over 65. They were evaluated after 6 months, 1 year and 2 years of treatment using Mini Mental State Examination (MMSE) and clock test.

1. Group A -43 patients treated with piracetamum(daily dose:1600 mg).

2. Group B that comprises 44 patients diagnosed with MCI treated with rhodiola rosea, 2 capsules/day.

3. Group C -41 patients which were treated with antioxidant agents(vitaminE 800ui/day).

4. Group D -36 subjects treated with piracetamum associated with rhodiola rosea and vitamin E.

5. Group E -29 patients without treatment.

Mean of MMSE score at inclusion was 24,49 (SD = 2,1). After 6 months of treatment MMSE score improve in groups treated with 1,35 points in group A, 1,41 for group B, 1,12 points for group C, 1,18 points in group D and in group E we observed an impairment with 0,52 points. in groups A, B, C and D after 1 year of treatment the improvement is with 2,07; 2,03, 2,68 and 3,03 points comparing with the impairment in group E of 1,69 points. Evaluation after 2 years of treatment show a better improvement for group D (3,3 points), followed by group C (2,63 points), group B (2,43 points) and group A (2,23 points) and a greater impairment in group E (2,49 points).

MCI has a better evolution in group treated with a combined therapy comparing with groups treated with monotherapy and in group E the patients present an impairment of cognitive function.